Therapy guide · medical education
Eczema: the full therapy pathway
From the moisturiser that genuinely is first-line to the biologics and light therapy dermatologists reach for when it isn't enough — what each step is, and why it sits where it does.
Before anything else
Not everyone should start at the bottom of this pathway. These presentations are reasons to
see a clinician without waiting out an over-the-counter trial first.
- Painful, punched-out sores or blisters appearing in crops, often with fever Seek care quickly
This can be eczema herpeticum — herpes simplex spreading across eczematous skin. It is a genuine dermatological emergency, it moves fast, and it needs antiviral treatment urgently rather than an appointment next month. If your eczema suddenly turns painful rather than itchy and studs over with uniform little erosions, that is the picture.
- Almost your whole skin red and shedding Seek care quickly
Widespread erythroderma affects temperature control and fluid balance and is treated as an emergency regardless of the underlying cause.
- Weeping, golden crusting, or spreading pain See a dermatologist soon
Infected eczema will not settle with emollients and topical steroids alone, and treating it as an ordinary flare loses time.
- Eczema that is costing you sleep See a dermatologist soon
Sleep loss is a recognised reason to escalate in its own right, whatever the lesion count. You do not need to look severe to qualify for effective treatment.
- Eczema appearing for the first time in adulthood, especially if it spreads or resists treatment Worth a clinician visit
New adult-onset eczema is worth a clinician's assessment rather than self-treatment — several conditions, including some that are not eczema at all, present this way.
- Eczema in a baby or young child Worth a clinician visit
Paediatric eczema differs in distribution, triggers and treatment thresholds, and this page is written for adults. It belongs with a clinician from the start.
Which part of this pathway is yours?
Four branches are mapped here and they are treated very differently. Six questions, about a minute, and the page narrows to the one that matches — including telling you when it cannot narrow honestly.
Answers stay in this browser. Nothing is transmitted, and one button clears them.
One thing to be clear about. This locates you on a map; it does not diagnose you. Scabies, contact dermatitis, psoriasis and fungal infection are all mistaken for eczema regularly, and none of them improve on this pathway. If what comes back does not match your experience, that mismatch is worth more than the form's answer.
What this looks like
Eczema is staged less by how much of you it covers than by what it is doing to you — how often it flares, how much it itches, and whether it is costing you sleep. Two people with the same body-surface area can be in very different trouble.
Mild
Dry, itchy patches that come and go and settle with regular emollients and the occasional short course of a mild steroid.
What it looks like: Rough, pink, itchy areas — commonly elbow creases, behind the knees, hands, neck. Sleep is intact. Weeks pass between flares.
Moderate
Frequent or near-continuous flares that need topical treatment more often than they don't.
What it looks like: Redder, thicker, sometimes weepy patches over larger areas; skin that has begun to lichenify — leathery and accentuated from chronic scratching. Itch interrupts sleep some nights.
Severe
Widespread, relentless disease that topical treatment cannot hold.
What it looks like: Extensive inflamed, cracked, oozing or thickened skin; nightly sleep loss; visible excoriation from scratching. This is the stage where the disease is running your life, and it is also where the most effective treatments live.
Three things that change the plan regardless of severity
Sleep loss
Itch that wakes you is not a minor symptom — it is the thing that turns eczema from a skin problem into a life problem, and it is a legitimate escalation reason on its own. Clinicians take it seriously; guidelines count it. If you are not sleeping, say so out loud at the appointment rather than describing only the rash.
Hands or face involved
Location outranks area. Hand eczema can end a career, and facial eczema is both the most visible and the site where potent steroids are least appropriate — both push toward a clinician earlier than the same amount of eczema on a shin would.
Skin that is weeping, crusted or getting worse fast
Eczematous skin is colonised skin, and infection is common. Golden crusting, weeping, spreading pain or fever change the plan entirely — that is a treatment problem, not a moisturising problem.
What it is doing to your head
Chronic itch is strongly linked to anxiety and depression, and the association runs both ways. This belongs in the consultation as much as the rash does, and it is not a soft add-on to the case for stronger treatment.
What else it could be
- Contact dermatitis — Eczema confined to an oddly specific area — a watch strap, a waistband, the eyelids — is often a reaction to something touching it, and patch testing rather than a stronger cream is the answer.
- Scabies — Intense itch that is worse at night, burrows in finger webs or wrists, and other people in the house itching too. It is regularly mistaken for eczema and it worsens on steroids.
- Psoriasis — Thicker, sharply-edged, silvery-scaled plaques on the outside of elbows and knees rather than in the creases.
- Fungal infection — An expanding ring with a clearer centre, often one-sided — and, like scabies, it grows on topical steroids.
The tell shared by scabies and fungal infection is instructive: both get worse on the steroid that should have helped. If your eczema reliably flares when treated, that is information — take it to a clinician rather than escalating the steroid.
Why it happens
Eczema is not dry skin that got out of hand. Two things are wrong at once: the skin's barrier leaks — often for genetic reasons, filaggrin being the best-known — so water escapes and irritants and allergens get in; and the immune system over-responds to what gets through, which produces the redness and the itch. The itch then drives scratching, scratching damages the barrier further, and the loop closes. That loop is why treatment works on two fronts at once: repair the barrier, and quiet the immune response. A moisturiser is doing the first job, and it is doing real work.
Adults who are managing eczema with moisturisers and drugstore hydrocortisone and want to know whether there is more — and adults whose eczema has already outgrown that. If you are looking for information about a baby or young child's eczema, this page is not it: paediatric eczema is genuinely different in its distribution, its triggers and its treatment thresholds, and it belongs with a clinician from the start.
Orientation, not diagnosis. This page helps you orient — it is not a diagnosis. Plenty of things look like eczema: contact dermatitis from something you touch, psoriasis, fungal infection, and — one worth naming out loud — scabies, which itches ferociously, is frequently treated as eczema for months, and gets worse on steroids. Adult-onset eczema that appears out of nowhere deserves a clinician's eye rather than a self-diagnosis.
No prescription needed for any of this The over-the-counter pathway
Here is the part that surprises people: for eczema, the pharmacy aisle is not a holding pattern. Emollients are first-line treatment in every guideline there is, and used properly they reduce flares, reduce how much steroid you end up needing, and are the only part of the plan you keep doing forever. The catch is 'used properly' — which means far more, far more often, and on skin that looks fine, not just skin that doesn't. Most emollient failures are dosing failures.
Appropriate for: Mild to moderate eczema in an adult: itchy dry patches, no weeping or crusting, no fever, sleep broadly intact. Not for infected skin, not for a first adult presentation that's spreading, and not for a child.
Emollients are not the preparation before eczema treatment — for mild disease they are the treatment, and the evidence for them is as good as it gets for anything on this page. Which is why this pathway is not about finding a better product. It is about using an ordinary one properly, because that is where almost every failed attempt actually comes apart.
Why this usually fails, and it isn't the product
Three things go wrong, in this order. People use far too little — an adult treating widespread eczema properly gets through 250 to 500 grams a week, and most get through a tube a month. They use it only when the skin is bad, which is the one time it cannot do its main job. And they pick by how it feels rather than what it does, so the greasiest and most effective options get abandoned first. Nothing further down this page compensates for any of that.
Four things that matter more than which tub you buy
- Quantity is the dose. If a tub lasts months rather than weeks, the treatment is not being given.
- Apply within a few minutes of washing, onto skin that is still damp — you are sealing water in, not adding it.
- Smooth it downwards in the direction the hair lies. Rubbing it in against the grain blocks follicles and can bring up spots.
- Keep going when the skin looks well. Emollients prevent the next flare; that work is invisible, and stopping is how the cycle restarts.
Answer as you go and the chart tracks where you are. Nothing is sent anywhere.
- TodayYou are here
Stop stripping the skin
Remove the things actively removing the barrier, before adding anything to rebuild it.
What this step involves
Morning
- Swap the soap Soap, shower gel and bubble bath strip the lipids eczema is already short of. Use an emollient wash or the emollient itself as a soap substitute — it will not lather, which is the point. Browse all cleansers →
- Cooler, shorter Hot water feels wonderful on an itch and leaves the skin worse an hour later. Lukewarm, and out in under ten minutes.
Evening
- Pat, don't rub Leave the skin slightly damp rather than towel-dry — that damp window is what the next step works on.
Why this step: Every one of these is free, and together they remove more irritation than most products add. Skin being stripped twice a day cannot be rebuilt by anything applied afterwards.
Ready for the next step?
Have you replaced soap and hot showers, everywhere on the body?
Yes, all swapped: Good — that is the floor everything else stands on. Go to step 1 ↓
Not yet: Start here. It costs nothing and it is the change most likely to make the next step work.
- Week 1You are here
Choose an emollient you will genuinely use
The right texture, which is a real trade-off rather than a marketing question.
What this step involves
Morning
- Pick by greasiness, not by brand Ointments work best and feel worst; creams are the usual compromise; lotions are mostly water and rarely enough on their own. A cream used four times a day beats an ointment abandoned on day three. Browse all moisturizers →
Evening
- Consider two Many people settle on a lighter one for daytime and a heavier one overnight. That is a sensible answer, not indecision. Browse all moisturizers →
Why this step: There is no meaningful evidence that one emollient outperforms another for most people. What does predict success is whether the texture is tolerable enough to be applied often, which is why the choice belongs to you rather than to a ranking.
What's normal: Anything that stings on application is wrong for you regardless of its reputation — stinging on eczematous skin usually means a fragrance or a preservative that will keep causing trouble.
Ready for the next step?
Have you found one you would happily put on several times a day?
Yes: Then the next step is the one that actually matters: how much. Go to step 2 ↓
Still hunting: Try a greasier one at night and a lighter one by day before concluding none of them suit you.
- Weeks 1–2You are here
Use enough of it
The step where most eczema treatment is won or lost.
What this step involves
Morning
- Everywhere, not just the patches Eczema-prone skin is abnormal between the patches too. Treat the whole limb, the whole torso — the visible spots are where it has broken through, not where it lives.
- Within minutes of washing Onto damp skin, downwards, without rubbing. Browse all moisturizers →
Evening
- Again before bed Night is when scratching does its damage. A generous layer before sleep is the single most useful application of the day.
- Heavier on the worst areas An ointment or a plain occlusive over the top of the usual emollient, on the areas that never quite settle. Browse all moisturizers →
Why this step: Quantities in guidelines look absurd until you measure your own: several hundred grams a week for an adult with widespread eczema. Most people are using a fraction of that and concluding the emollient does not work.
A practical check: buy it in a 500g tub rather than a 100ml tube. The tube size is most of the reason people under-use it.
Ready for the next step?
Are you applying at least twice a day, over whole areas rather than spots?
Yes: Then the treatment is genuinely being given, and the clock can start. Go to step 3 ↓
Not really: Fix this before anything else. An under-dosed emollient tested for six weeks tells you nothing except that it was under-dosed.
- OngoingYou are here
Carry on when the skin looks fine
Turn treatment into maintenance, which is where emollients earn most of their evidence.
What this step involves
Morning
- Same routine, clear skin Unchanged on good days. This is the application that prevents the next flare rather than settling the current one.
Evening
- Same again The habit survives better attached to washing and to bedtime than to how the skin looks that morning.
Why this step: Eczema relapses; that is what the disease does. Continuous emollient use reduces how often and how hard it comes back, and it is the only part of the plan that works while nothing is visibly wrong.
Ready for the next step?
Are you still applying on the days your skin looks well?
Yes: That is the habit the whole pathway rests on, and the hardest one to keep. Go to the checkpoint ↓
It slips: Very common, and worth attaching to something you already do daily rather than to a decision you have to make each morning.
Four to six weeks of a properly-dosed routine
Counted from when the quantity was right and the soap was gone — not from when you first bought a tub.
How to judge it: Look at frequency rather than at today's skin. How many flares in the last month, how many nights of broken sleep, how often you reached for something stronger. Eczema fluctuates enough that a single good or bad day tells you almost nothing.
Fewer flares, less itch, and fewer disturbed nights than a month ago?
Then this is the plan, and it does not have an end date.
For a lot of mild eczema this is the whole of treatment, indefinitely. The instruction that follows is the one people find hardest: do not stop when the skin is clear. Emollients are doing their most valuable work on days when there is nothing to see, and the commonest way a settled routine unravels is success.
Partly working — and that is a normal reason to add something, not to start again.
An emollient routine that reduces flares without stopping them has done its job and reached its limit. What is missing is something that treats inflammation once a flare has started, and that is a prescription question. Keep everything above exactly as it is; what comes next is added to it, never instead of it.
This is where the pathway hands over.
A properly-dosed emollient routine, kept up for a month or more, that has not moved the itch or the flare frequency has told you something useful: the barrier half of the problem is being managed and the immune half is not. That is not a failure of effort and it is not a sign you chose the wrong tub. It is the point at which treatment that acts on inflammation becomes the reasonable next step.
Stop and get it looked at.
Skin that is weeping, developing golden crusts, becoming painful or spreading quickly may be infected, and infected eczema does not settle with more emollient. Stinging with every application points at a reaction to the product itself rather than to the eczema. Either way the next move is a clinician, not a different tub.
Do not work through this list if any of these appear
Painful punched-out sores or blisters appearing in crops — especially with fever — need urgent attention the same day; that pattern can be a herpes infection spreading through eczematous skin. Widespread redness with shedding across most of the body is also an emergency. Neither waits for a treatment trial, and neither is treated with anything sold over a counter.
Eczema is a relapsing condition, so a plan that worked once is worth revisiting rather than assuming. Long stretches of treatment that never quite achieves control are worth taking back to a clinician instead of continuing on the assumption that this is simply how your skin is.
Where the over-the-counter pathway ends
Everything above is available without a prescription and none of it stops when a prescription starts — that is the part most often got wrong. Beyond here, treatment acts on the inflammation rather than the barrier, and it needs a clinician because the choice depends on where the eczema is, how thick the skin has become, and how long it has been running. If the next step turns out to be a topical steroid, that is an ordinary outcome: under-treated eczema does considerably more damage than a correctly-used steroid, and worry about them is itself one of the commonest reasons eczema stays bad.
See the prescription pathway →Eczema: the full therapy pathway · dermapproved.com/treatments/eczema/ · not a diagnosis — confirm anything you act on with a clinician
What to expect
Two expectations do most of the damage in eczema. The first is that treatment cures it — it doesn't; it controls it, and control is a state you maintain rather than a finish line you cross. The second is that visible skin is the measure — it isn't, and people routinely stop treatment the week it looks fine and restart the cycle. Whatever rung you are on, the pattern that works is the same: treat properly, keep the emollient going, and hold the result deliberately rather than waiting to see if it lasts.
- Use more emollient than feels reasonable, more often than feels necessary, including on skin that looks fine.
- Don't stop a topical the day it looks better — finish the course you were given, and ask about proactive maintenance.
- Steroid fear costs more skin than steroids do. If you're worried, ask what the actual plan is rather than quietly using half.
- Judge this over months. Eczema has good and bad weeks for reasons nobody can always identify.
This is where the site stays useful during clinical care rather than only before it: the emollient half of the plan is a product problem the catalog genuinely helps with, and it is the half you'll be doing for the rest of your life. The severity and itch tools give the appointment something better than an impression, and the routine layer handles the parts of a regimen a prescription doesn't cover.
What would bring you back sooner
Whatever step you are on, these do not wait for the end of a trial period. They are the same
presentations listed at the top of this page — repeated here because that is where they
matter, rather than where they were easiest to put.
- Painful, punched-out sores or blisters appearing in crops, often with fever Seek care quickly
- Almost your whole skin red and shedding Seek care quickly
- Weeping, golden crusting, or spreading pain See a dermatologist soon
- Eczema that is costing you sleep See a dermatologist soon
- Eczema appearing for the first time in adulthood, especially if it spreads or resists treatment Worth a clinician visit
- Eczema in a baby or young child Worth a clinician visit
Prescription only — from here on, this is a clinician's decision The prescription pathway
Why this tier exists. What the aisle cannot do: control moderate-to-severe disease, treat infected skin, break a flare that has already taken hold, or do anything about the immune half of the problem. Emollients manage the barrier. When the immune side is what's driving it, no amount of cream reaches that — and buying a thicker one is the commonest way people lose a year.
Eczema treatment isn't one ladder either — how far you go depends on severity, and on whether the skin has become infected. The whole structure fits on one screen: where each version tops out, and what has to happen before it climbs.
The same pathway in full below — each step names what it involves, why it sits where it does, and what tells you it's time to move up. Tap any therapy to jump to its detail.
Mild eczema
Itchy dry patches that come and go, settle with treatment, and leave your sleep alone. The barrier is the main problem here, and the aisle genuinely addresses it.
You reach this column when: Flares keep breaking through, you are reaching for hydrocortisone repeatedly, or the itch is starting to cost you sleep.
- Prescription topical
Prescription topicals
Why this step sits here: When emollients cannot hold it, guidelines add a topical anti-inflammatory — a corticosteroid matched to the site, or a calcineurin inhibitor where steroids are least appropriate, or one of the newer non-steroidal options. The emollient does not stop; it continues underneath.
Three kinds of anti-inflammatory cream sit on this rung, and none is a stronger edition of another. What separates them is where the eczema is and how long it is going to need treating:
- A topical corticosteroid, potency matched to the site backed by large randomized trials
The usual opening move almost everywhere — decades of trial evidence, quick to settle a flare, and cheap. Potency is chosen for the body part rather than for how angry the patch looks, which is why a tube for a face and a tube for a shin are rarely the same tube.
- A calcineurin inhibitor backed by large randomized trials
Eyelids, face, neck and folds, and skin that has already had a great deal of steroid. Nothing about it thins skin, so it suits the sites where that limit bites earliest — the trade is a stinging first week that usually settles.
- One of the newer non-steroidal creams backed by large randomized trials
Increasingly a first prescription rather than a fallback: steroid-free by design, and useful when itch is the loudest complaint or when steroids are unwanted. The catch is supply — which of them exists where you live changes by market and by year.
Which one, at what potency, and for how long depends on where your eczema is and what it has done to the skin already — a question about your face is a different question from one about your shins, and that is exactly what the appointment sorts out.
-
Moderate to severe eczema
Frequent or constant flares, widespread or thickened skin, and itch that interrupts your sleep. The immune half of the disease is driving this, and the ladder goes considerably further than most people realise.
You reach this column when: It is already moderate or severe, it is costing you sleep, or the skin is thickened from chronic scratching. Any of those, and this rung is a foundation rather than a trial.
- Prescription topical
Prescription topicals
Why this step sits here: Topical anti-inflammatories, matched to site and severity, and often used proactively — twice weekly to the places that always flare — rather than only reactively. Proactive use is the part most people are never told about, and it is what stops the cycle.
When to move up
- A fair trial
- Several weeks of a properly-dosed topical regimen, applied at the quantities your clinician specifies rather than the quantity that feels reasonable.
- Improvement looks like
- Flares that are shorter, milder and further apart; skin that stays settled between them; sleep returning.
- Move up if
- Disease stays widespread despite proper topical treatment, or you cannot realistically treat the area involved with creams, or the itch continues to run your nights.
→ The next step up this pathway.
Where are you with this step?
- Phototherapy
Phototherapy
Why this step sits here: For widespread disease, light treatment offers something no cream and no tablet does: it calms the skin broadly without putting a drug through the rest of you. Guidelines place it between topicals and systemic treatment for exactly that reason. Its cost is time — two or three trips a week for months.
When to move up
- A fair trial
- A course of two to three sessions a week over roughly two to three months.
- Improvement looks like
- Widespread calming and less itch, holding between sessions.
- Move up if
- It doesn't hold, or the travel makes it undoable — which is a legitimate reason, not a failure of commitment.
→ The next step up this pathway.
Where are you with this step?
- Prescription oral
Conventional systemic therapy
Why this step sits here: Broad immunosuppression — older, cheaper, monitored with regular blood tests. In much of the world this is the systemic tier, and where biologics are unaffordable it remains a legitimate and effective choice rather than a consolation.
One card, four drugs, and the differences between them are practical rather than a matter of strength:
- Ciclosporin, for a short stretch backed by large randomized trials
Acts within weeks, which makes it the usual pick when severe disease has to be broken quickly. Blood pressure and kidney function set the ceiling, and it is not a drug anyone stays on for years.
- Methotrexate, for the longer haul backed by large randomized trials
Slower to take hold and easier to continue. In the trial that ran the two against each other in children and young people, ciclosporin worked faster while methotrexate held its ground better after treatment stopped.
- Azathioprine or mycophenolate backed by smaller studies
Reached for when neither of the first two suits or can be continued. The evidence base is thinner, the wait for an effect is longer, and the blood monitoring is the same commitment.
When to move up
- A fair trial
- Weeks to months depending on the agent — cyclosporine acts within weeks, methotrexate takes longer.
- Improvement looks like
- Real control of widespread disease, with blood tests staying where they should.
- Move up if
- It doesn't control it, the monitoring or side effects aren't tolerable, or a targeted drug is available to you.
→ The next step up this pathway.
Where are you with this step?
-
- Biologic or JAK inhibitor
Biologics and JAK inhibitors
Why this step sits here: Drugs that block the specific signal driving eczema rather than suppressing the whole immune system. This is the tier that changed the disease: durable control for people who spent years being told to moisturise harder. Biologics are injected and need almost no monitoring; oral JAK inhibitors work faster and carry heavier warnings. Neither outranks the other — the choice is a conversation about speed, route, risk and cost.
What is actually on the menu here, and how a prescriber tells them apart:
- An IL-4/IL-13 biologic backed by large randomized trials
The longest track record of the group and the widest age licence, reaching down to infants. A fortnightly or monthly injection, no routine blood tests, and eye irritation as the side effect worth knowing about in advance.
- An IL-13 biologic backed by large randomized trials
The same family aimed one signal narrower. Often where a prescriber goes when the broader antibody was not tolerated, or when the maintenance interval on offer suits someone better.
- An IL-31 biologic, aimed at the itch backed by large randomized trials
Trialled on top of topical treatment rather than instead of it, and pointed at the itch signal specifically — which fits the person whose defining problem is scratching and lost sleep rather than how much skin is involved.
- An oral JAK inhibitor backed by large randomized trials
A tablet rather than an injection, and the quickest route to itch relief in the head-to-head trials. In exchange: screening before starting, blood tests throughout, and class warnings a biologic does not carry.
Nothing on this page decides between an injection every fortnight and a daily tablet with blood tests. That turns on how fast you need relief, how you feel about needles, what your insurer will cover, whether you might become pregnant, and what else is true about your health — which is the appointment, not the page.
-
Infected eczema or eczema herpeticum
Weeping, golden crusting, spreading pain, fever — or painful punched-out sores appearing in crops. This is not a flare to treat harder.
If this is you, stop reading the ladder. Infected eczema needs medical attention, and eczema herpeticum needs it today — it is one of the few genuine emergencies in dermatology and it moves quickly.
- Specialist care
Get seen — today if there are punched-out sores
Why this step sits here: Infection changes the treatment entirely, and eczema herpeticum is an emergency. Neither responds to emollients or to more steroid, and both get worse while you wait to see whether they settle.
There is no product step here and no clock to run down. Painful rather than itchy, spreading rather than static, feverish rather than just sore — any of those and this page's job is to get you to someone who can look at it.
Staying clear between flares
Eczema is a relapsing disease, so control is not the finish line — holding it is. Almost everything that goes wrong after a good result goes wrong here, when treatment stops the moment the skin looks fine and the cycle restarts a fortnight later.
Skin currently clear, flares in predictable places
Proactive maintenance: applying a topical anti-inflammatory two or three times a week to the sites that always flare, while they still look normal. It is counter-intuitive, it is well-evidenced, and it is the single most under-used idea in eczema care.
Skin currently clear, no obvious pattern
Emollients continue indefinitely. This is the part that never stops, and stopping it is the commonest reason a good result doesn't last.
On a systemic drug or biologic and doing well
The emollient carries on underneath. People who stop moisturising once a biologic is working generally find out why it was still on the plan.
Eczema: the full therapy pathway · dermapproved.com/treatments/eczema/ · not a diagnosis — confirm anything you act on with a clinician
When the rules change
The ladders above are written for an adult with eczema on adult skin. Three groups of readers need a different answer — and for one of them the honest answer is that this is the wrong page.
Eczema in pregnancy and while nursing
Eczema frequently gets worse in pregnancy rather than better, and the immune shift that causes it is ordinary rather than alarming. The reflex is to stop everything, which is where the trouble starts: uncontrolled inflammation and months of broken sleep are not a neutral alternative to treatment. Most of what works for mild and moderate disease stays available. It is the top of the ladder that narrows.
What can be used
- Emollients, in any quantity, throughout — the one part of the plan that nothing about pregnancy changes
- Topical corticosteroids, long used in pregnancy, with the potency and the amount weighed rather than the drug ruled out
- Phototherapy, often actively preferred for widespread disease precisely because nothing is absorbed into the rest of the body
- Where systemic treatment cannot be avoided, ciclosporin has the longest pregnancy record and is sometimes continued under specialist supervision
What comes off the table
- Methotrexate and mycophenolate, which cause birth defects — contraception during treatment and a planned gap before conceiving are part of how they are prescribed
- JAK inhibitor tablets, which are avoided in pregnancy and while breastfeeding
- Treating a biologic as either obviously fine or obviously forbidden — the registry data is accumulating and so far reassuring, and it is still an individual decision made with the specialist
Raise pregnancy plans before a systemic drug starts rather than after. Specialists in Europe work from a task-force position paper written specifically about treating eczema through preconception, pregnancy and lactation, so the answers exist — they are just much easier to apply in advance.
Babies, children and teenagers
Most eczema in the world is childhood eczema, and this page is deliberately not written for it: where it appears, what sets it off, when to treat harder and which drugs are licensed at all are different questions in a child, and they belong with a clinician from the start rather than to a self-managed ramp. One thing is worth knowing before that appointment, because parents are routinely surprised by it — the ladder does not stop at hydrocortisone for children. Most of the tiers on this page reach down into childhood at licensed ages.
- Under 2
- Emollients and swapping soap out do the heavy lifting, and prescribing is cautious: in most countries calcineurin inhibitors are not licensed below two years. Eczema in a baby that is spreading fast, weeping or crusting is a same-week question rather than a wait-and-see one.
- 2 to 11
- The steroid-sparing creams open up — crisaborole is licensed from three months, tapinarof from age two, and calcineurin inhibitors from two — and for severe disease the longest-established biologic is licensed down to six months of age.
- 12 to 17
- Effectively the adult ladder: the biologics and the oral JAK inhibitors are licensed from twelve. What gets missed at this age is what the disease costs in sleep, school and mood, and that is a legitimate reason to escalate on its own.
- Severe eczema in the first year of life
- Worth raising food allergy explicitly with the paediatric team — severe infant eczema is one of the recognised risk factors, and current national advice on introducing peanut early is close to the opposite of what parents were told a decade ago.
None of this replaces a paediatric assessment. The point is only that a parent walking into that appointment has more worth asking about than a stronger cream.
Eczema on brown and black skin
Redness is the sign every description of eczema leads with, and on deeper skin tones it is often the hardest one to see — inflammation can read as grey, violet, or simply darker than the skin around it, so severity gets under-scored by patients, by scoring tools and by clinicians alike. Two other differences matter: eczema more often shows up as small bumps around the follicles rather than broad plaques, and it can favour the outer surfaces of the limbs rather than the creases the textbooks describe. And it leaves more behind — pale or dark marks that outlast the flare by months and are regularly mistaken for the eczema still being active.
What can be used
- Everything on this page — nothing in the ladder itself changes with skin tone
- Photographs of a bad flare, taken in daylight, which counter an under-scored assessment better than any description
- Treating the inflammation promptly, which is also the most effective thing available for the marks it leaves behind
Those marks are not scars and they do fade, on a scale of months rather than weeks. Skin-lightening products are not the answer to them, and the pigment pages on this site are a separate conversation — settling the eczema is what shortens them.
How an appointment actually happens, what to take to it, and how to keep your skin liveable while a prescription or procedure does its work.
What seeing a dermatologist actually looks like
A GP manages a great deal of eczema competently, and in most systems is the route to everything above the topical tier anyway. Ask for a dermatology referral if topicals aren't holding it — the systemic and biologic tiers are specialist-prescribed almost everywhere, and getting into that queue early costs nothing.
What to bring
- Every treatment you've used, at what strength, for how long, and what happened. The eczema ladder is long, and the clinician's first job is finding out which rungs you have actually been up.
- How much emollient you get through in a week or a month. It is the single most diagnostic number you can bring, and it is usually far lower than people expect.
- How your sleep is. Not how the rash looks — how you are sleeping.
- Photos of a bad flare. Eczema has a habit of behaving on the day of the appointment.
- Whether you are pregnant, might be, or are nursing — it changes the systemic options substantially.
Questions worth asking
- Which of these is for my face, and which is for my body?
- How much should I actually be using, and for how long?
- Should I be treating the places that always flare even when they look fine?
- If this doesn't work, what's next — and can I get it here?
- Am I using enough emollient? Honestly?
Cost and access. Emollients, steroids and the conventional systemics are cheap and generic almost everywhere. Biologics and JAK inhibitors are not, and access is usually decided by insurers or national bodies rather than by clinical judgement — which means the honest conversation includes what you can actually get, not only what would be best. Ask directly; a good clinician expects it.
People routinely spend years managing eczema alone because they believe it is a cosmetic problem they should be able to handle, or because a steroid frightened them once. Neither is a good reason to keep losing sleep. If it is running your life, that is the whole indication.
Skincare alongside therapy
Eczema is unusual on this site: the supporting routine and the treatment are partly the same thing. Emollients are not adjuncts here — they are first-line therapy that continues under every rung above. What follows is how the rest of the routine changes as the treatment gets stronger.
One rule carries almost all of this: the emollient never stops. Not when the steroid starts, not when the biologic works, not when the skin looks perfect. Every treatment above assumes the barrier work is still happening underneath, and the commonest way a good result unravels is that someone finally felt well enough to stop moisturising.
While you're using a prescription topical
The two commonest errors here point in opposite directions: using far too little out of fear, and using a potent steroid on a face for months because nobody said not to. Both come from the same gap — nobody explained the plan.
Do
- Use the amount you were told to use. Under-treating a flare prolongs it, which ends up meaning more steroid overall, not less.
- Keep the emollient going underneath, and leave a few minutes between the two.
- Ask which tube is for which body part, and write it on the tube. Face and body are different answers.
- Ask about proactive maintenance — twice-weekly treatment to the places that always flare, once they're clear. Many people are never offered it.
Avoid
- Stopping the moment it looks better, then restarting three days later. That cycle is the disease winning.
- Potent steroids on the face or in folds unless you were specifically told to.
- Any active skincare on top — acids, retinoids, vitamin C. There is no version of this where they help.
What that looks like on a shelf: an emollient for everywhere, a gentle cleanser, an occlusive to seal at night.
While you're having phototherapy
A course means two or three trips a week for a couple of months. Everything else about your routine stays the same, with one addition: your skin is being deliberately exposed to UV, and what you put on it matters on the day.
Do
- Follow the unit's instructions about emollients before sessions — some are fine, some scatter the light and are not.
- Sunscreen on the parts not being treated, especially the face.
- Tell them about any new medication; several make you burn faster.
Avoid
- Topping up with sunbeds or sunbathing between sessions. This is a dose, and doubling it is how you get burnt.
- Assuming a mild burn is part of it. It isn't — tell them.
What that looks like on a shelf: an emollient for everywhere, a daily sunscreen, a gentle cleanser.
While you're on a systemic drug or a biologic
This is where people most often quietly stop moisturising, because for the first time in years they can. It is also the point where the skin barrier is still abnormal even though it looks normal — the drug is treating the immune half, not the barrier half.
Do
- Keep the emollient going. The barrier defect is genetic and it did not go away because your skin cleared.
- Keep whatever topical plan you were given for breakthrough patches — a biologic working well is not the same as never flaring.
- Get your monitoring bloods done on time if you're on a conventional systemic or a JAK — that's the deal.
- Tell any clinician you're on it before vaccines, surgery, or if you get a significant infection.
Avoid
- Treating clear skin as cured. It's controlled, which is a different and still very good thing.
- Quietly skipping blood tests because you feel fine — that is precisely when they matter.
What that looks like on a shelf: an emollient for everywhere, a gentle cleanser, a daily sunscreen.
The supporting shelf
An emollient for everywhere
A gentle cleanser
An occlusive to seal at night
A daily sunscreen
These are supporting products, and for eczema that phrase undersells them — emollients are first-line treatment in every guideline. They are ranked here on gentleness first: fragrance-free, low irritation risk, then score. A product missing from these lists isn't a bad product; it just isn't right for skin that is already inflamed.
Every therapy named above, in full. Look things up here; it is not meant to be read end to end.
Every therapy, explained
Reference, not reading — every therapy named anywhere above, described the way a clinician would describe it. Nobody reads this section end to end; open the one you were sent here for. Which one is right for you is the appointment's job, not this page's.
Over the counter
Available without a prescription. Each one opens with what to look for on a label, which is the part that stays true regardless of which brand is on the shelf that month.
Over-the-counter Emollients (ceramides)
Barrier-repair moisturisers
Generally compatible
Emollients (ceramides)
Barrier-repair moisturisers
The base of every eczema plan in every guideline — a ceramide-containing moisturiser used every day, in quantities most people badly underestimate.
Browse all ceramides products in our catalog →
How it works
Replaces the lipids a leaky barrier is short of and slows water loss, which reduces how often the immune system meets something it objects to. Fewer provocations, fewer flares.
What the evidence says well established
Moisturisers are foundational in the AAD's topical guideline for adults — they reduce disease severity and the amount of other treatment needed, which is a rare thing for something available without a prescription.
Typical course
Twice daily, every day, flare or no flare. An adult treating widespread eczema properly gets through a startling amount — if a tub lasts months, it isn't being used at treatment doses.
Commonly discussed side effects
- Occasional stinging on broken skin, usually from fragrance or a humectant
- Greasiness — the most effective ones are the least elegant
Worth knowing
- Apply after bathing, on damp skin, while the door of opportunity is open
- Fragrance-free, always — eczematous skin is primed to sensitise
Pregnancy: Emollients are the mainstay in pregnancy precisely because they carry no systemic exposure worth the name. This is one of the few parts of the plan that never needs revisiting.
Why it sits where it does: It sits at the base because it treats the barrier half of the disease, needs no prescription, and — unusually for a first rung — is never left behind: every rung above it keeps this one running underneath.
Over-the-counter Petrolatum and occlusives
Over-the-counter occlusive
Generally compatible
Petrolatum and occlusives
Over-the-counter occlusive
Plain ointment. The least interesting product in dermatology and one of the most useful.
Browse all petrolatum products in our catalog →
How it works
Forms a physical barrier that water cannot cross. It repairs nothing and needs to repair nothing — in a disease defined by leaking, simply stopping the leak does most of the work.
What the evidence says well established
Occlusive ointments are long-established in atopic dermatitis care, and are the vehicle of choice on cracked or fissured skin where anything else stings.
Typical course
At night, over the emollient, on the worst areas. Also the honest answer for hands and fingertips in winter.
Commonly discussed side effects
- Greasy; stains bedding
- Can feel intolerable in heat
Worth knowing
- Not for weeping or infected skin — sealing that in is the wrong move
Pregnancy: No meaningful systemic absorption; unrestricted in pregnancy and while nursing.
Why it sits where it does: It sits alongside the emollient rather than above it: the emollient supplies what's missing, the occlusive keeps it there. Neither is a step up from the other.
Over-the-counter Colloidal oatmeal
Over-the-counter anti-itch
Generally compatible
Colloidal oatmeal
Over-the-counter anti-itch
A finely-milled oat preparation with a long history and better evidence than its folk-remedy reputation suggests. Recognised as a skin protectant in its own right.
Browse all colloidal oatmeal products in our catalog →
How it works
Supplies beta-glucans and avenanthramides, which calm itch and support the barrier, alongside a straightforwardly emollient effect.
What the evidence says strong
Colloidal oatmeal is an established option for itch and barrier support in eczematous skin, and is one of the gentler things that can be put on inflamed skin without stinging.
Typical course
As an emollient, or as a bath additive during an itchy patch.
Commonly discussed side effects
- Rarely, sensitisation
- Slippery bath — a real hazard, not a footnote
Worth knowing
- Genuine oat allergy exists, though it is uncommon
Pregnancy: Topical colloidal oatmeal carries no systemic concern in pregnancy.
Why it sits where it does: It appears at the base as the option for skin too sore for anything else — its value is tolerability, not potency.
Over-the-counter Glycerin
Over-the-counter humectant
Generally compatible
Glycerin
Over-the-counter humectant
A humectant found in nearly every emollient, and one of the reasons the good ones work.
Browse all glycerin products in our catalog →
How it works
Draws water into the outer layers and holds it there. Pointless on its own in dry air — pair it with an occlusive or it hands the water straight back.
What the evidence says strong
Glycerin is among the best-supported humectants in barrier care and is a standard component of emollients used in atopic dermatitis.
Typical course
Continuous, as part of the emollient rather than a separate step.
Commonly discussed side effects
- Tacky at high concentrations
Worth knowing
- Works with an occlusive over it, not instead of one
Pregnancy: No systemic concern topically in pregnancy.
Why it sits where it does: It's a component of the base rung rather than a step of its own — named because knowing why an emollient works helps you pick one that does.
Browse the whole catalog for this condition:
What changed recently: Over-the-counter hydrocortisone 1% is the one drug in this aisle. It is genuinely useful for short courses on small areas, and genuinely unequal to the job on the face, in the folds, or for weeks on end — the situations where people most often reach for it. Its limits are the reason the prescription tier exists, not a failure of nerve.
Prescriptions and procedures
About the brand names below. Brand names are what the pharmacy label says; the generic name underneath is what matters, and it is the same molecule whichever box it arrives in. Eczema is the clearest case on this site of geography deciding treatment — a drug that is standard in one country may be unlicensed in the next, and this tier changes yearly. Treat the lists below as orientation, not a stock check. Where a region is missing, that reflects what we could verify rather than proof of absence.
These links go to manufacturers' labels and national medicines information — the documents a prescriber reads rather than a summary of them. Two cautions specific to this page: several of these drugs are licensed at different ages, and for different conditions, in different countries, so a label written for another market may not describe what is on offer where you are; and how much to use, on which part of the body, is decided person by person, which is the one thing no label can tell you.
Prescription topical Topical corticosteroids
Prescription anti-inflammatories, by potency
Individualized — ask a clinician
Topical corticosteroids
Prescription anti-inflammatories, by potency
The workhorse of eczema treatment and the most misunderstood drug on this page — feared into ineffectiveness by people applying far too little for far too short a time.
- Mild (e.g. hydrocortisone) — Face, folds, and the shortest courses.
- Moderate to potent — Body, limbs, thicker skin; chosen by site and severity.
- Very potent — Short, supervised courses for lichenified or resistant areas.
Read the label
- Hydrocortisone for skin — how and when to use it NHS (UK)
- FDA labels for triamcinolone acetonide cream DailyMed (US National Library of Medicine)
How it works
Damps the immune response driving the flare. The barrier work continues underneath with emollients; the steroid handles the inflammation the emollient cannot reach.
What the evidence says well established
Topical corticosteroids are a strongly-recommended first-line prescription treatment in the AAD's adult topical guideline, matched to the site and the severity rather than used at one strength everywhere.
Typical course
Applied to inflamed skin until it settles, then stopped or stepped down — and for some people, continued twice weekly to the sites that always flare. Potency is matched to the body part, which is why the tube for your face is not the tube for your shins.
Commonly discussed side effects
- Skin thinning with prolonged potent use on the same site
- Stretch marks in folds
- Rarely, perioral dermatitis from facial use
Monitoring
A clinician reviews how much you are getting through — quantity used over time is the honest measure of whether the plan is working.
Worth knowing
- Steroid phobia is itself a documented cause of treatment failure: the commonest error is using too little, too late, for too short a time
- Never on skin you suspect is infected or fungal without saying so
Pregnancy: Topical corticosteroids are widely used in pregnancy, with potency and quantity considered rather than avoided outright. Discuss the site and amount with a clinician.
Why it sits where it does: It is the first prescription rung because it directly treats the inflammatory half of the disease, which nothing in the aisle reaches — and because decades of use make its risks unusually well characterised.
Prescription topical Topical calcineurin inhibitors
Non-steroidal prescription topicals
Individualized — ask a clinician
Topical calcineurin inhibitors
Non-steroidal prescription topicals
Steroid-free anti-inflammatories designed for exactly the places steroids struggle — the face, the eyelids, the skin folds.
- Tacrolimus ointment — The more potent of the two; used on face, eyelids and folds where steroids are least appropriate.
- Pimecrolimus cream — Milder; often used for maintenance on delicate sites.
What it's called at the pharmacy
Generic names Tacrolimus ointment · Pimecrolimus cream
Sold as
- Protopic — tacrolimus ointment
- Elidel — pimecrolimus cream
- Protopic — tacrolimus ointment
- Elidel — pimecrolimus cream
Both are long off-patent and are widely dispensed generically — the generic tube is the same drug as the branded one.
Read the label
- FDA labels for tacrolimus ointment DailyMed (US National Library of Medicine)
- FDA labels for pimecrolimus cream DailyMed (US National Library of Medicine)
How it works
Blocks calcineurin and so the T-cell signalling that drives the flare, without the skin-thinning that limits long-term steroid use on delicate sites.
What the evidence says well established
Topical calcineurin inhibitors are recommended in the AAD adult topical guideline and are particularly valuable at sites where corticosteroid use is constrained.
Typical course
Twice daily during flares; also used proactively two or three times a week on sites that recur.
Commonly discussed side effects
- Burning or stinging in the first days — common, and it usually settles
- Flushing with alcohol in some people
Worth knowing
- The boxed warning about malignancy has not been borne out by long-term data, and it causes more under-treatment than it prevents harm — worth raising explicitly with your clinician rather than quietly not using it
Pregnancy: Systemic absorption is low, but use in pregnancy is decided case by case with a clinician rather than assumed either way.
Why it sits where it does: It sits on the same rung as steroids rather than above them: not stronger, but usable where steroids are not, which for facial and flexural eczema makes it the right first choice rather than the second.
Prescription topical Newer non-steroidal topicals
PDE4, AhR and topical JAK
Individualized — ask a clinician
Newer non-steroidal topicals
PDE4, AhR and topical JAK
A genuinely new tier: steroid-free topicals that arrived in the last few years and changed what 'topical treatment' can achieve.
- Crisaborole — A PDE4 inhibitor for mild-to-moderate disease.
- Roflumilast cream — A newer, more potent PDE4 inhibitor.
- Tapinarof cream — An aryl hydrocarbon receptor agonist, approved for atopic dermatitis from age 2.
- Ruxolitinib cream — A topical JAK inhibitor — the most potent of this group, with the most caveats.
What it's called at the pharmacy
Generic names Crisaborole · Roflumilast cream · Tapinarof cream · Ruxolitinib cream
Sold as
- Eucrisa — crisaborole
- Zoryve — roflumilast cream
- Vtama — tapinarof cream
- Opzelura — ruxolitinib cream
- Staquis — crisaborole
- Corectim — delgocitinib ointment, a topical JAK not available in the US or Europe for this use
This is the tier where where you live matters most — several of these exist in one market and not another, and the list changes yearly.
Read the label
- FDA label for crisaborole ointment DailyMed (US National Library of Medicine)
- FDA label for Zoryve (roflumilast) cream DailyMed (US National Library of Medicine)
- FDA label for Vtama (tapinarof) cream DailyMed (US National Library of Medicine)
- FDA label for Opzelura (ruxolitinib) cream DailyMed (US National Library of Medicine)
How it works
Different targets, same goal — interrupting the inflammatory signalling in the skin without a steroid. The topical JAK inhibitor blocks the pathway that carries the itch signal itself, which is why it can quiet itch quickly.
What the evidence says strong
The AAD's focused update for adults incorporates the most recently approved therapies into the existing guideline; tapinarof and roflumilast creams are among the agents recommended for atopic dermatitis in adults.
Typical course
Applied to affected skin, typically twice daily; ruxolitinib cream is limited in both duration and how much of your body it may cover.
Commonly discussed side effects
- Application-site burning or stinging
- Ruxolitinib cream carries the JAK class boxed warning despite being topical
Monitoring
Ruxolitinib cream has explicit limits on body-surface area and duration; a clinician tracks both.
Worth knowing
- This tier moves fast — what is available where you live may have changed since this page was reviewed
Pregnancy: All are newer agents with limited pregnancy data. Anyone pregnant, planning to be, or nursing should have that conversation before starting one.
Why it sits where it does: It shares the prescription-topical rung with steroids and calcineurin inhibitors, and earns its place by widening what can be done without either — especially for people who cannot keep using steroids on the sites that keep flaring.
Procedure Phototherapy
Narrowband UVB light treatment
Generally compatible
Phototherapy
Narrowband UVB light treatment
Controlled ultraviolet light delivered in a clinic cabinet, two or three times a week. Not a sunbed, and not sunbathing — the wavelength, dose and monitoring are the entire point.
How it works
Narrowband UVB suppresses the skin's immune activity locally, calming widespread disease without a systemic drug.
What the evidence says well established
Phototherapy is recommended in the AAD guideline covering phototherapy and systemic therapies for adults with atopic dermatitis, and it occupies a distinct place between topicals and systemic treatment.
Typical course
Two or three hospital visits a week for two to three months. The logistics are the main reason people decline it, and they are a legitimate reason.
Commonly discussed side effects
- Burning if the dose is misjudged
- Cumulative photoageing over many courses
- Tanning
Monitoring
Cumulative lifetime dose is tracked; a clinician weighs long-term skin-cancer risk against benefit.
Worth knowing
- Requires repeated travel to a unit — genuinely impractical for many people, and worth saying so rather than agreeing and not going
Pregnancy: Narrowband UVB is one of the treatments most often chosen during pregnancy for widespread disease, precisely because nothing is being taken systemically. Confirm with the treating clinician.
Why it sits where it does: It sits between topicals and systemic drugs because it treats widespread disease without exposing the rest of the body to a drug — the trade is time and travel instead of systemic risk.
Prescription oral Conventional systemic therapy
Older immunosuppressants
Avoid in pregnancy
Conventional systemic therapy
Older immunosuppressants
The systemic drugs that predate the biologics — broad immunosuppression, still useful, and still the most available option in much of the world.
- Cyclosporine — Works fast; used for short periods to break severe disease.
- Methotrexate — Slower, cheaper, long-established.
- Azathioprine, mycophenolate — Alternatives where the above don't suit.
What it's called at the pharmacy
Generic names Cyclosporine · Methotrexate · Azathioprine, mycophenolate
Sold as
- Ciclosporin / cyclosporine, methotrexate, azathioprine and mycophenolate are all long off-patent and dispensed generically almost everywhere
Where biologics are unaffordable or unavailable, this tier is not a lesser option — it is the option, and it is what most of the world uses.
Read the label
- Methotrexate — patient drug information MedlinePlus (US National Library of Medicine)
- FDA labels for cyclosporine DailyMed (US National Library of Medicine)
How it works
Suppresses the immune system generally rather than targeting one signal, which is both why they work and why they are monitored closely.
What the evidence says well established
Conventional systemic immunosuppressants are addressed in the AAD guideline on phototherapy and systemic therapies for adults, and retain a role — particularly where access or cost puts biologics out of reach.
Typical course
Cyclosporine in short bursts to regain control; methotrexate weekly over longer periods.
Commonly discussed side effects
- Cyclosporine: blood pressure and kidney effects
- Methotrexate: liver effects, nausea, bone-marrow suppression
Monitoring
Regular blood tests throughout — non-negotiable and the main practical burden of this tier.
Worth knowing
- Broad immunosuppression means infection risk; live vaccines need planning
Pregnancy: Methotrexate and mycophenolate are teratogenic and must not be taken in pregnancy, with contraception required and a washout period before conceiving — for either partner in the case of methotrexate. Cyclosporine is handled differently and is sometimes continued under specialist supervision. Raise pregnancy plans before starting anything in this group.
Why it sits where it does: It sits above topicals and phototherapy because it accepts systemic risk in exchange for control of disease nothing local can hold — and below the targeted drugs because it suppresses everything rather than the one thing that's wrong.
Biologics
Targeted injected antibodies
Individualized — ask a clinician
Biologics
Targeted injected antibodies
Injections that block one specific immune signal rather than dialling the whole system down. They are the reason severe eczema is a different disease to have in 2026 than it was in 2016.
- Dupilumab — Blocks IL-4 and IL-13 signalling; the longest track record and the widest age approval, from 6 months.
- Tralokinumab — Targets IL-13 alone.
- Lebrikizumab — Targets IL-13; approved in the US in 2024.
- Nemolizumab — Blocks IL-31 — the itch signal specifically; approved in the US in 2024.
What it's called at the pharmacy
Generic names Dupilumab · Tralokinumab · Lebrikizumab · Nemolizumab
Sold as
- Dupixent — dupilumab
- Adbry — tralokinumab
- Ebglyss — lebrikizumab
- Nemluvio — nemolizumab
- Dupixent — dupilumab
- Adtralza — tralokinumab
- Ebglyss — lebrikizumab
- Dupixent — dupilumab
- Adtralza — tralokinumab
Tralokinumab is the same drug under two names: Adbry in the United States, Adtralza almost everywhere else. If you have read about one and been offered the other, nothing has changed.
Read the label
- FDA label for Dupixent (dupilumab) DailyMed (US National Library of Medicine)
- FDA label for Adbry (tralokinumab) DailyMed (US National Library of Medicine)
- FDA label for Ebglyss (lebrikizumab) DailyMed (US National Library of Medicine)
- FDA label for Nemluvio (nemolizumab) DailyMed (US National Library of Medicine)
How it works
Monoclonal antibodies that intercept a single cytokine driving eczema. Because the target is narrow, the collateral effect on the rest of the immune system is far smaller than with conventional immunosuppressants — which is why they need no routine blood monitoring.
What the evidence says well established
The AAD guideline on systemic therapies recommends biologic treatment with concomitant topical therapy for adults with moderate-to-severe disease, and its 2025 focused update adds the most recently approved agents.
Typical course
A self-administered injection every two to four weeks, continued long term. Many people notice itch settling before the skin looks better — which is usually the change that matters most to them.
Commonly discussed side effects
- Injection-site reactions
- Conjunctivitis — notably with dupilumab, and usually manageable
- Cold sores in some people
Monitoring
No routine blood monitoring for most — a real practical advantage over the conventional tier.
Worth knowing
- Cost and insurance are the usual barrier rather than clinical suitability
- Given alongside topical treatment, not instead of it
Pregnancy: Registry data on dupilumab in pregnancy is accumulating and reassuring so far, but the decision is individual and belongs with a specialist. Raise pregnancy plans early — this is a long-term treatment and the conversation is easier before starting than after.
Why it sits where it does: It sits at the top for moderate-to-severe disease because it targets the specific signal rather than the whole immune system: more effective than the conventional tier for most people, and less burdensome to monitor.
Oral JAK inhibitors
Targeted oral small molecules
Avoid in pregnancy
Oral JAK inhibitors
Targeted oral small molecules
Tablets that block the intracellular signalling several eczema cytokines share. Fast — often the fastest itch relief available — and carrying the most serious warnings of anything on this page.
- Abrocitinib — JAK1-selective.
- Upadacitinib — JAK1-selective; the fastest-acting option in this group for many people.
- Baricitinib — JAK1/2; availability varies by country.
What it's called at the pharmacy
Generic names Abrocitinib · Upadacitinib · Baricitinib
Sold as
- Cibinqo — abrocitinib
- Rinvoq — upadacitinib
- Cibinqo — abrocitinib
- Rinvoq — upadacitinib
- Olumiant — baricitinib, licensed for atopic dermatitis in Europe but not in the US
Baricitinib is the clearest example on this page of a drug being a routine option in one market and simply not on the menu in another.
Read the label
- FDA label for Rinvoq (upadacitinib) DailyMed (US National Library of Medicine)
- FDA label for Cibinqo (abrocitinib) DailyMed (US National Library of Medicine)
How it works
Inhibits Janus kinases, interrupting several inflammatory signals at once inside the cell rather than intercepting one cytokine outside it. Breadth is why they work quickly and why the safety profile demands more care.
What the evidence says well established
JAK inhibitors are covered by the AAD guideline on systemic therapies for adults with atopic dermatitis, and are effective for moderate-to-severe disease.
Typical course
A daily tablet. Itch often improves within days, which for someone who has not slept properly in years is the headline.
Commonly discussed side effects
- Acne
- Raised cholesterol
- Infections, including shingles
- Blood-count changes
Monitoring
Regular blood tests, and screening before starting. The class carries boxed warnings covering serious infection, mortality, malignancy, major cardiovascular events and thrombosis, drawn largely from studies in a different, older population with rheumatoid arthritis.
Worth knowing
- Where the boxed warning's evidence comes from — and how well it transfers to a younger person with eczema — is a real and unsettled conversation to have with your specialist, not a reason to dismiss the drug or to wave the warning away
Pregnancy: JAK inhibitors are avoided in pregnancy, and effective contraception is expected during treatment. Raise pregnancy plans before starting.
Why it sits where it does: It shares the top rung with biologics rather than sitting above them: comparable or faster in effect, oral rather than injected, and carrying a monitoring and risk burden the biologics do not — which is why the choice between them is a conversation, not a ranking.
Prescription oral Treating infected eczema
Antibiotics and antivirals
Individualized — ask a clinician
Treating infected eczema
Antibiotics and antivirals
Eczema that has become infected is a different problem needing different treatment — and recognising it is the point of this card.
Read the label
How it works
Eczematous skin is heavily colonised with Staphylococcus aureus, and broken skin lets it in. Herpes simplex on eczematous skin causes eczema herpeticum, which is an emergency.
What the evidence says well established
Managing infection is a standard part of atopic dermatitis care; antibiotics are directed at clinical infection rather than used routinely, because routine use drives resistance without improving eczema.
Typical course
A defined course directed at what is actually there. Eczema herpeticum needs antiviral treatment urgently.
Commonly discussed side effects
- The usual antibiotic effects
- Antibiotic resistance with repeated courses
Monitoring
A clinician decides whether infection is present — swabs sometimes, judgement often.
Worth knowing
- Antibiotics are not a treatment for uninfected eczema, and using them that way costs you a future option
- Painful punched-out sores are not an ordinary flare — that is the emergency picture
Pregnancy: Antibiotic and antiviral choice in pregnancy is a clinician's decision; several standard options are compatible and several are not.
Why it sits where it does: It sits outside the ladder entirely — infection is not a rung to escalate to but a fork that interrupts the plan until it is dealt with.
On the horizon
Pipeline information current as of 2026-07-16
Only treatments in phase 3 or later. Eczema has an unusually crowded pipeline and most of it is earlier than that — reporting phase 2 promise as though it were arriving is how people end up waiting for something that never comes.
This changes nothing about what to do now. None of this changes what to do now. Eczema already has more effective treatment available today than at any point in its history; waiting for the next one while your sleep is being destroyed is the wrong trade.
Recently arrived
Lebrikizumab (Ebglyss) and nemolizumab (Nemluvio) (2024). Two biologics approved in the US in 2024 — lebrikizumab targeting IL-13, and nemolizumab targeting IL-31, the itch signal specifically. Nemolizumab is notable for going at itch directly rather than treating the rash and hoping the itch follows.
In late-stage development
Amlitelimab
Phase 3Sanofi
An injected antibody against OX40-Ligand — a different target from the IL-4/13/31 drugs already on the market, aimed further upstream.
Why it's notable: Phase 3 results presented at the AAD meeting in March 2026 met their endpoints, and the dosing studied stretches as far as every twelve weeks, which would be a genuine change in burden from a fortnightly injection.
Phase 3 data reported in 2026; not yet approved. Two cases of Kaposi sarcoma were reported across roughly 3,778 exposed patients, which is the kind of signal that gets scrutinised closely before approval.
Rocatinlimab
Phase 3 — development discontinuedAmgen / Kyowa Kirin
An anti-OX40 antibody that reached phase 3 with positive results.
Why it's notable: It is here as a corrective rather than a promise. It worked in phase 3 — and Kyowa Kirin then discontinued the trials after two new cancer cases emerged, abandoning a planned 2026 FDA submission.
Discontinued. This is what the phase-3-only rule is for: a drug can clear efficacy and still not arrive, and anyone who spent 2025 waiting for this one lost that time.
Beyond these, eczema has one of the busiest development pipelines in dermatology — more OX40-directed antibodies, more topical JAK inhibitors, and microbiome-directed treatments. Most are earlier than phase 3 and are deliberately not listed. This section is re-reviewed on its own faster schedule than the rest of the page.
Bleach baths, probiotics, elimination diets — where they actually stand
Eczema attracts more advice than almost any other skin condition, and a surprising amount of it has been properly tested. Here is what those trials found, including the entries where the popular answer turned out to be no.
- Bleach baths backed by smaller studies
Roughly swimming-pool strength, and a careful review including unpublished data did find an improvement in severity. The catch is that plain water baths improved things too, and the margin between the two is small and uncertain. A sensible measure for skin that keeps getting infected; not the missing piece for eczema that is simply inflamed.
- Emollient bath additives limited evidence
Tested properly in a large trial of children already using leave-on emollients, and they added nothing measurable over that routine alone. The money goes further on the emollient that stays on the skin, which is where the evidence has always been.
- Probiotics limited evidence
For eczema you already have, the Cochrane review found little or no difference in symptoms or quality of life. Whether they prevent eczema in high-risk infants is a separate and still-open question — treating established disease is not a use the evidence supports.
- Elimination diets and broad food-allergy testing limited evidence
Food allergy is genuinely more common alongside eczema, and this still goes wrong in a specific way: allergy tests throw up positives that mean nothing on their own, and diets built on them cause nutritional harm without settling skin. Testing earns its place where a food reliably causes an immediate reaction, or where a young child's severe eczema is not responding to proper treatment — with a clinician, not off a home kit.
- Dust-mite covers, filters and stripping out soft furnishings limited evidence
The Cochrane review of avoidance measures concluded the evidence was too weak to guide practice. Worth the effort only where a specific sensitivity has been documented and someone is watching whether the skin actually answers.
- Antihistamines limited evidence
The itch of eczema is not mainly histamine-driven, and the review evidence shows non-sedating antihistamines do not touch it. A sedating one at night is a different proposition with an honest rationale — it is being taken for sleep during a bad stretch, not as a treatment for the skin.
- Melatonin for the sleep half backed by smaller studies
A randomised crossover trial in children with eczema and disturbed sleep found it shortened the time taken to fall asleep and modestly improved disease severity. Small, single-centre and in children — but a more evidence-backed thing to try for broken sleep than most of what is marketed for it.
- Plant oils straight from the kitchen limited evidence
Not interchangeable, and the difference is not trivial: in a study of adult skin, olive oil measurably damaged the barrier where sunflower seed oil did not. That is reason enough not to treat 'natural oils' as one category. If the job is an emollient, an emollient is what does it.
Common questions
Is moisturiser really a treatment, or is that just what you say when there's nothing else?
It is genuinely treatment, and it is first-line in every guideline for atopic dermatitis. Half of eczema is a leaking barrier, and emollients address that half directly — they reduce flares and reduce how much steroid you need over time. What they cannot do is touch the immune half, which is why they stop being enough as disease gets more severe. The mistake isn't believing in moisturiser; it's believing it can do the whole job.
How much emollient should I actually be using?
Far more than you are. An adult treating widespread eczema properly gets through a quantity that surprises people — if a tub is lasting you months, it is not being used at treatment doses. The other half of the answer is timing: within about three minutes of getting out of the bath or shower, onto damp skin, and onto areas that look fine as well as areas that don't.
Will topical steroids thin my skin?
Prolonged use of potent steroids on the same area can, which is why potency is matched to the body part and why the face and folds get different treatment. But steroid phobia is itself a documented cause of treatment failure, and the far commoner outcome is someone using too little for too short a time, never settling the flare, and needing more steroid overall as a result. If you're worried, ask for the plan explicitly — how much, where, how long, and when to stop — rather than quietly halving it.
What's the difference between a biologic and a JAK inhibitor, and why would I get one over the other?
A biologic is an injection that blocks one specific immune signal; a JAK inhibitor is a tablet that blocks several signalling pathways inside the cell. JAKs tend to work faster and are excellent for itch, but carry class boxed warnings and need regular blood tests. Biologics are slower off the mark and need almost no monitoring. Neither is simply better — the choice turns on how fast you need relief, needles versus tablets, monitoring, pregnancy plans, and what you can actually get funded.
My eczema gets worse when I use the steroid. What's going on?
That is worth taking seriously rather than escalating. Both scabies and fungal infection are regularly mistaken for eczema and both get worse on topical steroids, and a contact allergy — sometimes to an ingredient in the cream itself — can do the same. Eczema that reliably flares when treated is information, and it needs a clinician's eye rather than a stronger tube.
Can I use my eczema treatment while pregnant?
Some of it, and the answer splits by tier. Emollients are unrestricted and remain the mainstay. Topical steroids are widely used, with potency and quantity considered. Phototherapy is often the preferred option for widespread disease precisely because nothing is taken systemically. But methotrexate and mycophenolate are teratogenic and must be avoided, and JAK inhibitors are avoided too. Raise it early — before starting a systemic drug is a much easier conversation than after.
The other 133 questions
Everything that doesn’t fit on a therapy ladder — side effects, timelines, pregnancy, cost, the things people get told that aren’t true. Here are the ones asked most.
- Is this eczema or just dry skin? Itch is the dividing line. Dry skin is rough and tight; eczema itches, comes in defined patches, and flares and settles rather than staying constant.
- What actually causes eczema? A leaky skin barrier and an over-reactive immune system, both largely inherited. The barrier lets irritants and allergens in; the immune system over-responds to them.
- Is topical steroid withdrawal a real thing? A withdrawal reaction after prolonged potent steroid use is recognised, though evidence is thin and contested — and fear of it drives far more undertreated eczema than the syndrome itself.
- Am I using enough emollient? By weight, not by feel. An adult treating widespread eczema needs roughly 250–500 g a week; if a 500 g tub lasts a month, you are using a fraction of the dose.
- Which moisturiser should I actually buy? The greasiest one you will genuinely use in large amounts, fragrance-free, in a big tub. Brand matters far less than quantity and how often it goes on.
- How long should a flare take to settle? With adequate treatment, most flares improve within a few days and settle in one to two weeks. Longer than that means the treatment is too weak, too little, or the diagnosis is wrong.
- What are the actual risks of topical steroids? Real but dose-dependent and mostly local: thinning, stretch marks, visible vessels and acneiform eruptions, almost always after prolonged potent use on thin skin.
- What if I'm frightened of the steroid I've been given? Say so at the appointment. Undisclosed non-use looks identical to treatment failure, and it leads to escalation you may not need — there are non-steroid options.
- What is proactive or weekend therapy? Applying an anti-inflammatory to your usual trouble spots twice a week once they are clear, to stop flares starting — rather than waiting and treating each one.
- What strength of steroid am I on, and does it matter? It matters a great deal. Potency runs from mild to very potent, and the right one depends on the site, the thickness of the patch and your age — not on caution alone.
- Is my eczema treatment safe in pregnancy? Emollients and topical steroids are considered compatible, and mild-to-moderate potencies are first-line. Methotrexate and JAK inhibitors are not, and must be stopped beforehand.
- My baby has eczema — what do I do first? Emollient generously and often, a non-soap wash, and a mild steroid on the active patches. Treating early and properly matters more than any product choice.
- Why doesn't my eczema look red like the pictures? In deeply pigmented skin, eczema often appears violet, grey or dark brown rather than red — which leads to severity being underestimated by patients and clinicians alike.
- What helps when the itching is worst at night? Cool the room, apply emollient generously before bed, cover the worst areas, and treat the inflammation properly — night itch is a severity signal, not a habit.
- Is it normal to feel this low about my skin? Yes. Eczema is strongly associated with depression, anxiety and sleep loss, and the association tracks itch and sleep far more than how the skin looks.
- What is eczema herpeticum and how would I spot it? A herpes virus infection spreading across eczematous skin — crops of painful punched-out sores or blisters, often with fever. It is a medical emergency needing same-day care.
Sources and further reading
The staging, escalation points, and therapy descriptions on this page are anchored to published clinical guidelines rather than editorial judgment.
What this page is built on
- Guidelines of care for the management of atopic dermatitis in adults with topical therapies
- Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies
- Focused update: Guidelines of care for the management of atopic dermatitis in adults
The studies behind this pathway
The trials and reviews this page leans on, beyond the guidelines listed above. Each link was resolved against the PubMed record in the same session it was written — a citation here with no link would mean the paper is real and the link could not be confirmed, which is a trade this site makes deliberately.
- Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations The second guideline this page is read against: a GRADE appraisal of the same treatments by an allergy-body panel, and the source for where the adjuncts at the foot of the page sit.
- Emollients and moisturisers for eczema The Cochrane review behind treating emollients as therapy rather than preparation — fewer flares, and less topical steroid needed alongside them.
- Frequent Versus Infrequent Bathing in Pediatric Atopic Dermatitis: A Randomized Clinical Trial Where the pathway's timing rule comes from: soaking twice a day and sealing immediately beat the same routine done twice a week.
- Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials Proactive treatment — applying an anti-inflammatory to skin that already looks well, on a schedule — pooled across trials of both steroids and calcineurin inhibitors.
- Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle Three-times-weekly tacrolimus to sites that had cleared: more flare-free days and longer to relapse than vehicle. The evidence under the maintenance sections.
- Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis The meta-analysis that found no increased cancer risk with topical calcineurin inhibitors — the basis for raising the boxed warning as a conversation rather than a barrier.
- Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial Five years of pimecrolimus in children, the long-run safety data the label's warning language predates.
- Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials The two phase 3 trials behind roflumilast cream's place on the non-steroidal rung.
- Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials Tapinarof cream's pivotal trials, run in adults and in children down to age two.
- Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies Pooled phase 3 results for ruxolitinib cream in adolescents — the topical JAK inhibitor's efficacy and its long-term disease-control data.
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis The trials that opened the biologic era in eczema, and the reference point every later systemic agent is measured against.
- Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis Lebrikizumab's two phase 3 trials, one of the two IL-13 antibodies on the targeted rung.
- Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials Nemolizumab given on top of topical treatment — the trials behind the itch-directed option and its use alongside, not instead of, creams.
- Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2) Tralokinumab's 52-week phase 3 programme, including the maintenance data.
- Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials Upadacitinib's replicate phase 3 trials in adults and adolescents.
- Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial The head-to-head that made the JAK-versus-biologic choice a real conversation rather than a hierarchy.
- Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update A living network meta-analysis comparing the systemic drugs against one another — the honest source for how close the targeted options actually are.
- Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial Ciclosporin against methotrexate in children and young people: one faster to act, the other steadier once treatment stopped.
- When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council The expert-panel answer to the question this page's checkpoint asks — when eczema warrants systemic treatment at all.
- Bleach baths for atopic dermatitis: A systematic review and meta-analysis including unpublished data, Bayesian interpretation, and GRADE Bleach baths appraised properly, including unpublished data: an effect on severity, but a thin margin over plain bathing.
- Probiotics for treating eczema The Cochrane review of probiotics for treating established eczema — little to no difference in symptoms or quality of life.
- House dust mite reduction and avoidance measures for treating eczema House dust mite avoidance measures, and why the evidence is too weak to build a plan on.
- An assessment of the use of antihistamines in the management of atopic dermatitis Why antihistamines do not treat eczema itch, and the narrow case where a sedating one still earns its place.
- Melatonin Supplementation for Children With Atopic Dermatitis and Sleep Disturbance: A Randomized Clinical Trial Melatonin for children with eczema and disturbed sleep — shorter time to fall asleep, and a modest improvement in severity.
- Emollient bath additives for the treatment of childhood eczema (BATHE): multicentre pragmatic parallel group randomised controlled trial of clinical and cost effectiveness The pragmatic trial that tested emollient bath additives on top of standard care in children and found no meaningful benefit.
- Effect of olive and sunflower seed oil on the adult skin barrier: implications for neonatal skin care Olive oil damaged the adult skin barrier where sunflower seed oil did not — the study behind not treating plant oils as a category.
- European Task Force on Atopic Dermatitis (ETFAD) Position Paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period The European task force position paper on treating eczema through preconception, pregnancy and lactation, and the basis of that section.
- Atopic dermatitis in diverse racial and ethnic groups-Variations in epidemiology, genetics, clinical presentation and treatment How eczema differs across racial and ethnic groups in presentation and severity — the source for the section on darker skin.
Eczema is unusually well served by sources with nothing to sell: two national charities, two national health services and the guideline bodies themselves all publish for patients rather than only for clinicians.
Clinical guidelines
Written for clinicians. The three American Academy of Dermatology guidelines this page follows are listed in the sources above; these two sit alongside them.
- Atopic eczema in under 12s: diagnosis and management (CG57) National Institute for Health and Care Excellence (UK) The UK paediatric guideline — the source for the stepped-care approach, the emollient quantities, and when a child should be referred.
- Atopic dermatitis (eczema) guidelines 2023 — AAAAI/ACAAI Joint Task Force Annals of Allergy, Asthma & Immunology The allergy bodies' GRADE-based appraisal, which grades the same treatments by certainty of evidence and covers the adjuncts the dermatology guidelines mostly leave alone.
Patient education from medical bodies
Written to be read by the person with the eczema.
- Atopic eczema — overview NHS (UK) What it is and when to involve a pharmacist or a GP, at the shortest useful length.
- Atopic eczema — treatment NHS (UK) Emollients, steroid potency and what happens above them, described at the level a first appointment will.
- Atopic dermatitis: overview and treatment American Academy of Dermatology How dermatologists approach it, from the body that writes the US guideline.
- Atopic dermatitis DermNet (New Zealand) More clinical than the rest, and the usual first stop for what a pattern or a complication is called.
- Eczema — health topic MedlinePlus, US National Library of Medicine A starting point rather than an article — it collects the research summaries, trials and specialist bodies in one place, none of which is trying to sell a cream.
Patient organisations
Charities and specialist centres — the practical end, and the best source for the things clinicians rarely have time to demonstrate.
- National Eczema Association National Eczema Association (US) Research summaries, an ingredient seal programme and support networks.
- Eczema UK — help, support and research Eczema UK (formerly the National Eczema Society) The UK charity's information booklets, including the most practical emollient guidance published anywhere.
- Eczema and Inflammatory Skin Disease Center Rady Children's Health (US) A paediatric centre's teaching resources — video demonstrations of the things a written instruction never quite conveys, wet wraps among them.
Take the charts with you
Print exactly the piece you need. Each chart is one landscape page — no prose, no controls, sized to pin up or hand to someone — and the full document is the whole pathway as it reads on screen. Every printout carries the date, the source, and a line making clear it is not a diagnosis.
Printing happens in your browser. Your answers stay private — saved on this device, and to your free account when you're signed in.